Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endo Health Solutions Inc To Acquire Specialty Pharmaceutical Company Paladin Labs Inc


Tuesday, 5 Nov 2013 06:30am EST 

Endo Health Solutions Inc announced that it has reached a definitive agreement to acquire Paladin Labs Inc., a Canada-based specialty pharmaceutical company, in a stock and cash transaction valued at approximately $1.6 billion of which approximately 98% will be paid in shares of stock as described below. The acquisition accelerates Endo's strategic transformation to a global specialty healthcare company and creates a platform for future growth in North America and internationally. Pursuant to the acquisition, each of Endo and Paladin Labs will be acquired by a newly-formed Irish holding company (New Endo). At $77.00 (CAD) per Paladin Labs share, the transaction represents a 20% premium to Paladin Labs' share price of $63.91 as of November 4, 2013, and is expected to be immediately accretive to Endo's 2014 adjusted earnings per share. 

Company Quote

68.34
-1.18 -1.70%
30 Sep 2014